Differences

This shows you the differences between two versions of the page.

--- home:mp [08.21.2017] – [Olmesartan (Benicar)] sallieq
+++ home:mp [10.16.2017] – [Stopping olmesartan] sallieq
@@ Line 60: / Line 60: @@
   * Patients on the MP should not take nimesulide (Aulin / Mesulid / Nimed).  It could cause bleeding. One death has been reported during its use.
   * Rivaroxaban (Xarelto) increases the risk of bleeding and can cause serious or fatal bleeding. A specific antidote for rivaroxaban is not available.
+  * Do not give Telmisartan, it has an over strong action in suppressing the patient's ability to fight infection.
   * Azithromycin is no longer regarded as safe, even in the small quantities formerly recommended for optional use while on MP
   * **For sicker patients, immunopathology can be physically and mentally challenging** –  Support from a knowledgeable doctor and family/friends becomes of paramount importance. Unless the patient has a good insight into IP and other inconveniences of the treatment, the patient should not start treatment.
@@ Line 240: / Line 241: @@
 ==== Stopping olmesartan ====
-Olmesartan will need to be [[home:mp:break:olmesartan#stopping_olmesartan|weaned gradually]]. Note that the immune response may remain activated for a period of time even after discontinuing olmesartan. Patients who stop olmesartan are terminating their recovery.
+Olmesartan will need to be [[home:mp:break:olmesartan#stopping_olmesartan|weaned very gradually]]. Note that the immune response may remain activated for a period of time even after discontinuing olmesartan. Patients who stop olmesartan are terminating their recovery.

home/mp.txt · Last modified: 09.14.2022 by 127.0.0.1